Optimization of Morphomer-based Alpha-synuclein PET Tracers

Related Clinical Trial
Optimization of Morphomer-based Alpha-synuclein PET Tracers Evaluation of [18F]APN-1607 as a PET Biomarker A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP) RT001 in Patients With Progressive Supranuclear Palsy (PSP) PROGRESSIVE SUPRANUCLEAR PALSY Complex Eye Movements in Parkinson’s Disease and Related Movement Disorders tDCS and Speech Therapy for Motor Speech Disorders Caused by FTLD Syndromes: a Feasibility Study Application od Machine Learning Method in Validation of Screening Cognitive Test for Parkinsonisms Subcutaneous Apomorphine in the Treatment of Progressive Supranuclear Palsy and Cortico Basal Degeneration (APOPARKA) Remote Monitoring in Progressive Supranuclear Palsy (PSP) Trial of Parkinson’s And Zoledronic Acid Rho Kinase (ROCK) Inhibitor in Tauopathies – 1 UPenn Observational Research Repository on Neurodegenerative Disease Evaluation of Imaging Characteristics of [18F]PI-2620 PET in AD and PSP Patients Using High and Low Specific Activity Systematic Assessment of Laryngopharyngeal Function in Patients With MSA, PD, and 4repeat Tauopathies The MOTIVE-PSP Initiative A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy Efficacy and Safety of Transcranial dIrect Current stiMulation (tDCS) in Progressive Supranuclear Palsy (PSP) (STIM-PSP) Image Characteristic and Longitudinal Follow up of 18F-PMPBB3 (APN-1607) PET for Progressive Supranuclear Palsy Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy Misfolded Proteins in the Skin of People With Parkinson’s Disease and Other Parkinsonism Neurodegenerative Diseases Registry Transcranial Magnetic Stimulation in Progressive Supranuclear Palsy 18F-PM-PBB3 PET Study in Tauopathy Including Alzheimer’s Disease, Other Dementias and Normal Controls Brain Network Activation in Patients With Movement Disorders Neurologic Stem Cell Treatment Study ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) Transcranial Duplex Scanning and Single Photon Emission Computer Tomography (SPECT) in Parkinsonian Syndromes ADDIA Proof-of-Performance Clinical Study Defining Phenotypes of Movement Disorders :Parkinson’s Plus Disorders (PD), Essential Tremor (ET), Cortical Basal Degeneration (CBD), Multiple Systems Atrophy (MSA), Magnetoencephalography. Gait Analysis in Neurological Disease Diagnosing Frontotemporal Lobar Degeneration Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies Study of the Neural Basis of Analogical Reasoning Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Phase 1 Test-retest Evaluation of [18F]MNI-958 PET Diagnostic and Prognostic Biomarkers in Parkinson Disease Tau Imaging With JNJ067 Research of Biomarkers in Parkinson Disease More Than a Movement Disorder: Applying Palliative Care to Parkinson’s Disease Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism Identifying Biomarkers of Parkinson’s Disease Using Magnetic Resonance Imaging (MRI) Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) Davunetide (AL-108) in Predicted Tauopathies – Pilot Study Robot Walking Rehabilitation in Parkinson’s Disease Human CNS Tau Kinetics in Tauopathies 4-Repeat Tauopathy Neuroimaging Initiative – Cycle 2 In-Home Care for Patients With PSP and Related Disorders Facilitating Diagnostics and Prognostics of Parkinsonian Syndromes Using Neuroimaging Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA) Biomarkers in Parkinsonian Syndromes Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain Effects of Coenzyme Q10 in PSP and CBD 2-(1-{6-[(2-[F-18]Fluoroethyl) (Methyl)Amino]-2-naphthyl} Ethylidene) Malononitrile-PET for in Vivo Diagnose of Tauopathy in Unclassified Parkinsonism Oxford Study of Quantification in Parkinsonism A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects The Neural Basis for Frontotemporal Degeneration Analysis of the Enteric Nervous System Using Colonic Biopsies Evaluation of Tolfenamic Acid in Individuals With PSP at 12-Weeks Chromatic Pupillometry to Assess the Melanopsin-Light Pathway in Progressive Supranuclear Palsy 4 Repeat Tauopathy Neuroimaging Initiative A Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 in Patients With PSP Foot Mechanical Stimulation for Treatment of Gait and Gait Related Disorders in Parkinson’s Disease and Progressive Supranuclear Palsy. Safety Study of TPI-287 to Treat CBS and PSP Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain Neuroprotection and Natural History in Parkinson’s Plus Syndromes (NNIPPS) Efficacy Study for Treatment of Dementia in Progressive Supranuclear Palsy A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy Pathophysiology of Gait and Posture in Progressive Supranuclear Palsy A Pilot Clinical Trial of Pyruvate, Creatine, and Niacinamide in Progressive Supranuclear Palsy. Clinical Trial to Evaluate Bone Marrow Stem Cell Therapy for PSP, a Rare Form of Parkinsonism tDCS Plus Physical Therapy for Progressive Supranuclear Palsy Repetitive Transcranial Magnetic Stimulation (TMS) for Progressive Supranuclear Palsy and Corticobasal Degeneration Risk Factors for Progressive Supranuclear Palsy (PSP) Continuously Infused Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (GDNF) to Treat Progressive Supranuclear Palsy Cerebellar rTMS Theta Burst for Postural Instability in Progressive Supranuclear Palsy Neuropsychological Evaluation for Early Diagnosis of PSP Evaluating Cerebrospinal Fluid Biomarkers in Alzheimer’s, Progressive Supranuclear Palsy Subjects, and Controls A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal Degeneration Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104 Study About Safety and Efficacy of Coenzyme Q10 in Progressive Supranuclear Palsy Study of the Distractibility Syndrome in Patients With Progressive Supranuclear Palsy Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003 PROgressive Supranuclear Palsy CorTico-Basal Syndrome Multiple System Atrophy Longitudinal Study UK The Study to Evaluate the Safety and Efficacy of Spinal Cord Stimulation on Progressive Supranuclear Palsy Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy Young Plasma Transfusions for Progressive Supranuclear Palsy Study of BIIB092 in Participants With Progressive Supranuclear Palsy A Study to Test the Safety and Tolerability of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP) Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy Deep TMS for the Treatment of Patients With Parkinson’s Disease and Progressive Supranuclear Palsy Rehabilitation in Patients With Progressive Supranuclear Palsy A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP) Quality of Life of the Patient and the Burden of the Caregiver in Progressive Supranuclear Palsy An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP). Trial of Valproic Acid in Patients With Progressive Supranuclear Palsy (Depakine) Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy Efficacy, Tolerability and Safety of Azilect in Subjects With Progressive Supranuclear Palsy Postural Instability in Progressive Supranuclear Palsy

Brief Title

Optimization of Morphomer-based Alpha-synuclein PET Tracers

Official Title

Optimization of Morphomer-based Alpha-synuclein PET Tracers

Brief Summary

      The aim of the project is to develop the first alpha-synuclein (a-syn)-specific PET tracer.
      The research phase will exploit ACI's proprietary MorphomerTM library and extensively
      optimized screening workflow.

      Promising PET-tracer candidates will be tested for their ability in detecting a-syn pathology
      in patients with a range of Parkinsonian conditions with different a-syn levels and
      distributions, comprising hereditary forms of PD and other synucleinopathies.
    

Detailed Description

      Aims:

      Today there is no way of detecting a-synuclein pathology in life, and thus the diagnoses of
      Parkinson's Disease (PD) and the closely related synucleinopathies Dementia with Lewy Bodies
      (DLB) and Multiple system atrophy (MSA) are clinical diagnoses, that can be supported by
      dopamine (F-DOPA) imaging and biomarkers (f.ex cerebrospinal fluid neurofilament light
      chain), but where the ultimate diagnosis is not certain until at post mortem investigation of
      the brain.

      The general aim of this study is to assess a newly developed positron emission tomography
      (PET) tracers for a-synuclein and to study the ability of the tracer in detecting the
      underlying pathology in PD, DLB and MSA. If the PET tracers can detect the pathology reliably
      our hope is that this tracers can assist in future clinical trials for PD, DLB and MSA.

      Primary aim

      • to assess the brain a-synuclein load in vivo using [18F]ACI-3847 PET in MSA, DLB and
      Parkinson's disease

      Secondary aims

        -  to explore the correlation in these patients between a-synuclein load assessed by
           [18F]ACI-3847 PET and clinical features including cognitive impairment and severity of
           neurological symptoms

        -  to detect a-synuclein pathology assessed by [18F]ACI-3847 PET in Parkinson cases with a
           duplication in the gene coding for a-synuclein

      Background:

      Clinical presentation: Neurodegenerative disorders mainly affect the elderly population and
      approximately 1% of the population above 60 are affected by PD. DLB is likely underdiagnosed,
      but represent approximately 10% of the patients in a specialist dementia center setting. MSA
      is more uncommon and is often mistaken for PD, but carries a much worse prognosis. Due to the
      poor prognosis of MSA it is important to as early as possible be able to give a correct
      diagnosis.

      The diagnoses of PD, DLB and MSA are today mainly clinical diagnoses. The diagnosis of PD is
      based on the triad of symptoms: rigidity, resting tremor and bradykinesia of movement,
      followed by a rapid and sustained response of symptoms to levodopa treatment. Further, the
      loss of dopaminergic neurons can be visualized with PET-imaging of dopamine storage capacity
      (18F-DOPA PET). At symptom onset of PD it has been estimated that 50-70% of dopaminergic
      cells are already lost, making it more difficult to successfully treat the disease to halt or
      slow down disease progression. MSA causes similar symptoms as PD, and is often mistaken for
      PD, but patients gradually also develop autonomic failure, with varying heart rate and
      blodpressure, causing falls due to ortostatic drops in blood pressure. F-DOPA PET again shows
      a loss of dopaminergic cells in the midbrain, but the levodopa response is much attenuated in
      MSA. DLB shows similar symptoms of bradykinesia and rigidity, but also early on changes in
      cognition and visual hallucinations.

      Neuropathology: PD, DLB and MSA are all caused by aggregation of a-synuclein in the brain.
      The midbrain and the brainstem is first affected in PD, and later in the disease the
      pathology spreads throughout the neocortex. In DLB the a-synuclein often also involves the
      occipital neocortex and limbic brain structures in addition to the midbrain. In MSA the
      pathology affects the brain stem and basal ganglia, but also often the cerebellum.

      Diagnostic work-up: As stated earlier there is today no reliable way to verify the diagnoses
      or the a-synuclein in life. In this study we will include also 18F-DOPA PET that is today the
      state-of-the-art technique for detecting a loss of dopamine producing cells in the midbrain.
      18F-DOPA PET will strengthen the diagnostic accuracy, but there are still pitfalls even when
      using 18F-DOPA PET for diagnosis. For example the Parkinson-related disorders Progressive
      Supranuclear Palsy (PSP) and Corticobasal Degeneration (CDB), that both show dopamine cell
      loss and a decreased 18F-DOPA retention in addition to PD-like symptoms like bradykinesia and
      rigidity, but that both are caused by tau pathology and not a-synuclein pathology. It is well
      known that the diagnostic accuracy of some of the diagnoses with parkinsonism is at best
      moderate and that many diagnoses will have to be corrected at autopsy.

      Our hope is that [18F]ACI-3847 PET in the long run will help in the differential diagnosis
      against PSP and CBD, but also that the different patterns of a-synuclein accumulation in PD,
      DLB and MSA will provide a useful tool in tracking disease progression within the
      synucleinopathies.

      Treatment trials: There are currently no treatments that slow down or stop PD, DLB or MSA.
      There are large efforts to develop therapies (e.g. immunotherapies) that remove aggregated
      a-synuclein from the brains of the affected patients. However, there is no methods available
      today that can be used to study whether such treatments really affect the levels of abnormal
      a-synuclein in the living human brain. If [18F]ACI-3847 PET can visualize the a-synuclein
      aggregates, then it might be used in the future to evaluate whether novel therapies can
      remove a-synuclein from the brain of living humans.

      Participants:

      Patients with PD, DLB, MSA, PSP and CBD and Healthy controls.

      Inclusion criteria - patients

        -  Age 50-100 years.

        -  Fulfill the criteria for PD, DLB, MSA, PSP or CBS.

        -  Speaks and understands Swedish to the extent that an interpreter was not necessary for
           the patient to fully understand the study information and cognitive tests.

      Exclusion criteria - patients

        -  Significant unstable systemic illness or organ failure, such as terminal cancer, that
           makes it difficult to participate in the study.

        -  Current significant alcohol or substance misuse.

        -  Refusing MRI or PET.

      Inclusion criteria - healthy controls

        -  Age 50-100 years

        -  Absence of cognitive symptoms or parkinsonism as assessed by a physician with special
           interest in cognitive disorders.

        -  Speaks and understands Swedish to the extent that an interpreter is not necessary for
           the patient to fully understand the study information and cognitive tests.

      Exclusion criteria - healthy controls

        -  Significant unstable systemic illness or organ failure, such as terminal cancer, that
           makes it difficult to participate in the study.

        -  No significant neurological or psychiatric disease.

        -  Current significant alcohol or substance misuse.

        -  Refusing MRI or PET.

      Methods:

      Positron Emission Tomography [18F]ACI-3847 PET (a-synuclein PET) will be performed in all
      participants. 185 MBq (5 mCi) [18F]ACI-3847 is injected intravenously via an intravenous
      cathether. Data acquisition is started at the time of injection and continues over 100
      minutes (0-100 min). During this time the patient will need to keep as still as possible.
      Image data will be collected on GE Discovery MI PET/CT cameras as LIST mode data (raw data)
      and be reconstructed after acquisition and attenuation correction. Arterial sampling will be
      performed in a subset of individuals.

      [18F]DOPA PET for assessment of remaining dopamine producing cells will be performed by
      intravenous injection of 185 MBq (5 mCi) [18F]DOPA. Data acquisition is started at either at
      the time of injection and continues over 110 minutes, or starts 90 min after injection and
      continues for 20 minutes. No arterial blood sampling is needed for this scan.

      Magnetic Resonance Imaging 3 Tesla MRI (Siemens Prisma) will be done in all participants. No
      contrast-enhancing agent will be used.
    


Study Type

Observational


Primary Outcome

Detection of alpha-synuclein pathology


Condition

Parkinson Disease


Study Arms / Comparison Groups

 Parkinson's Disease
Description:  Patients with Parkinson's Disease. Patients will undergo [18F]ACI-3847 PET, [18F]DOPA PET and MRI. Up to 20 patients will be scanned

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information



Estimated Enrollment

12

Start Date

July 15, 2021

Completion Date

September 1, 2021

Primary Completion Date

September 1, 2021

Eligibility Criteria

        Inclusion Criteria:

          -  Age 50-100 years.

          -  Fulfill the criteria for PD, DLB, MSA, PSP or CBS. Alongside with these participants
             patients with duplications in the gene coding for a-synuclein will be included.

          -  Absence of cognitive symptoms or parkinsonism as assessed by a physician with special
             interest in cognitive disorders (Healthy controls).

          -  Speaks and understands Swedish to the extent that an interpreter was not necessary for
             the patient to fully understand the study information and cognitive tests.

        Exclusion Criteria:

          -  Significant unstable systemic illness or organ failure, such as terminal cancer, that
             makes it difficult to participate in the study.

          -  Current significant alcohol or substance misuse.

          -  Refusing MRI or PET.
      

Gender

All

Ages

50 Years - N/A

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

Oskar Hansson, Professor, , 

Location Countries

Sweden

Location Countries

Sweden

Administrative Informations


NCT ID

NCT05067192

Organization ID

A-synuclein-PET-study


Responsible Party

Principal Investigator

Study Sponsor

Skane University Hospital

Collaborators

 AC Immune SA

Study Sponsor

Oskar Hansson, Professor, Principal Investigator, Skane University Hospital


Verification Date

September 2021